GlassScriptPhysician profile
Helen Etemadi
NPI 1215917133
$2,767.87
in general payments reported to CMS, 2019-2025
38 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $206 · 2021: $303 · 2022: $573 · 2023: $355 · 2024: $518 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.71 | 2019-2025 | |
| Astellas Pharma US INC | $295.74 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $275.43 | 2021-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $163.61 | 2019-2024 | |
| Aspira Women'S Health INC | $146.30 | 2020-2022 | |
| Minerva Surgical, INC | $143.60 | 2019 | |
| Avion Pharmaceuticals | $120.96 | 2019-2023 | Balcoltra |
| Medtronic, INC. | $102.54 | 2024 | Closurefast |
| Coopersurgical, INC. | $87.97 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Sage Therapeutics, LLC | $73.36 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $72.05 | 2021-2022 | |
| Agile Therapeutics, INC. | $71.09 | 2021-2023 | Twirla |
| Mayne Pharma Commercial LLC | $65.41 | 2022-2023 | |
| Lupin INC. | $63.62 | 2019-2020 | |
| Solventum Corporation | $56.99 | 2024 | Prevena, V.A.C.Ulta, V.A.C. Veraflo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $50.12 | 2023-2024 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $43.99 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $41.16 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $40.82 | 2019-2022 | |
| Ethicon US, LLC | $35.52 | 2025 | Vistaseal |
| Exact Sciences Corporation | $34.60 | 2023-2025 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $34.02 | 2019 | |
| Exeltis, USA INC. | $33.01 | 2021-2025 | Slynd |
| Amag Pharmaceuticals, INC. | $32.76 | 2019 | |
| Dysis Medical, INC. | $24.17 | 2021 | |
| Davol INC. | $23.83 | 2025 | Arista |
| Scynexis, INC. | $22.90 | 2021 | |
| Supernus Pharmaceuticals, INC. | $20.99 | 2025 | Qelbree |
| Pacira Pharmaceuticals Incorporated | $19.68 | 2025 | Exparel |
| Baxter Healthcare | $18.62 | 2025 | Perclot |
| Vertical Pharmaceuticals, LLC | $17.82 | 2019 | |
| Mission Pharmacal Company | $15.30 | 2020 | |
| Becton, Dickinson and Company | $14.37 | 2023 | Bd Onclarity |
| Bayer Healthcare Pharmaceuticals INC. | $13.98 | 2019 | |
| Novo Nordisk INC | $13.62 | 2023 | |
| Kci USA, INC. | $13.04 | 2023 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Organon LLC | $12.50 | 2023 | Nexplanon |
| Allergan, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Etemadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.